Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Nov;64(5):884–886. doi: 10.1038/bjc.1991.419

Pyridinium crosslinks as markers of bone resorption in patients with breast cancer.

C R Paterson 1, S P Robins 1, J M Horobin 1, P E Preece 1, A Cuschieri 1
PMCID: PMC1977489  PMID: 1931610

Abstract

Collagen breakdown, and thus bone resorption, can now be assessed by measuring the urinary excretion of the collagen crosslinks, pyridinoline (Pyd) and deoxypyridinoline (Dpd). In a pilot study we measured Pyd and Dpd in 20 patients with breast cancer, ten with known bone metastases and ten with no recognised metastases in bone or elsewhere after 1 year's subsequent follow up. Eight out of the ten patients with metastases had crosslink excretion values higher than the reference interval, but so did some patients without known metastatic disease. For both crosslinks there was a clear correlation with serum alkaline phosphatase activity measured at about the same time. We consider that measurement of urinary collagen crosslink assays may have a place in the early detection of metastatic spread to bone.

Full text

PDF
884

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertolini D. R., Nedwin G. E., Bringman T. S., Smith D. D., Mundy G. R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature. 1986 Feb 6;319(6053):516–518. doi: 10.1038/319516a0. [DOI] [PubMed] [Google Scholar]
  2. Black D., Duncan A., Robins S. P. Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal Biochem. 1988 Feb 15;169(1):197–203. doi: 10.1016/0003-2697(88)90274-6. [DOI] [PubMed] [Google Scholar]
  3. Cuschieri A. Urinary hydroxyproline in the management of breast cancer. World J Surg. 1977 May;1(3):299–302. doi: 10.1007/BF01556842. [DOI] [PubMed] [Google Scholar]
  4. Deacon A. C., Hulme P., Hesp R., Green J. R., Tellez M., Reeve J. Estimation of whole body bone resorption rate: a comparison of urinary total hydroxyproline excretion with two radioisotopic tracer methods in osteoporosis. Clin Chim Acta. 1987 Jul 15;166(2-3):297–306. doi: 10.1016/0009-8981(87)90433-5. [DOI] [PubMed] [Google Scholar]
  5. Eyre D. R., Koob T. J., Van Ness K. P. Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography. Anal Biochem. 1984 Mar;137(2):380–388. doi: 10.1016/0003-2697(84)90101-5. [DOI] [PubMed] [Google Scholar]
  6. Frenay M., Namer M., Boublil J. L., Khater R., Viot M., François E., Milano G. Value of urinary hydroxyproline and bone isoenzyme of alkaline phosphatase in the early detection and follow-up of bone metastasis in breast cancer patients. Bull Cancer. 1988;75(6):533–539. [PubMed] [Google Scholar]
  7. Fujimoto D. Isolation and characterization of a fluorescent material in bovine achilles tendon collagen. Biochem Biophys Res Commun. 1977 Jun 20;76(4):1124–1129. doi: 10.1016/0006-291x(77)90972-x. [DOI] [PubMed] [Google Scholar]
  8. Gunja-Smith Z., Boucek R. J. Collagen cross-linking compounds in human urine. Biochem J. 1981 Sep 1;197(3):759–762. doi: 10.1042/bj1970759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kivirikko K. I. Urinary excretion of hydroxyproline in health and disease. Int Rev Connect Tissue Res. 1970;5:93–163. doi: 10.1016/b978-0-12-363705-5.50008-7. [DOI] [PubMed] [Google Scholar]
  10. Krane S. M., Kantrowitz F. G., Byrne M., Pinnell S. R., Singer F. R. Urinary excretion of hydroxylysine and its glycosides as an index of collagen degradation. J Clin Invest. 1977 May;59(5):819–827. doi: 10.1172/JCI108704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ogawa T., Ono T., Tsuda M., Kawanishi Y. A novel fluor in insoluble collagen: a crosslinking moiety in collagen molecule. Biochem Biophys Res Commun. 1982 Aug 31;107(4):1252–1257. doi: 10.1016/s0006-291x(82)80132-0. [DOI] [PubMed] [Google Scholar]
  12. Roberts J. G., Williams M., Henk J. M., Bligh A. S., Baum M. The hypronosticon test in breast cancer. Clin Oncol. 1975 Mar;1(1):33–43. [PubMed] [Google Scholar]
  13. Robins S. P. An enzyme-linked immunoassay for the collagen cross-link pyridinoline. Biochem J. 1982 Dec 1;207(3):617–620. doi: 10.1042/bj2070617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Robins S. P. Cross-linking of collagen. Isolation, structural characterization and glycosylation of pyridinoline. Biochem J. 1983 Oct 1;215(1):167–173. doi: 10.1042/bj2150167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Robins S. P., Stewart P., Astbury C., Bird H. A. Measurement of the cross linking compound, pyridinoline, in urine as an index of collagen degradation in joint disease. Ann Rheum Dis. 1986 Dec;45(12):969–973. doi: 10.1136/ard.45.12.969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Seibel M. J., Duncan A., Robins S. P. Urinary hydroxy-pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases. J Rheumatol. 1989 Jul;16(7):964–970. [PubMed] [Google Scholar]
  17. Stepán J. J., Mikulecký M., Bek V., Broulík P., Pacovský V. Bone alkaline phosphatase isoenzyme and urinary hydroxyproline in healthy subjects, patients with osteolytic metastases, and patients with primary hyperparathyroidism. Neoplasma. 1989;36(4):495–501. [PubMed] [Google Scholar]
  18. Uebelhart D., Gineyts E., Chapuy M. C., Delmas P. D. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner. 1990 Jan;8(1):87–96. doi: 10.1016/0169-6009(91)90143-n. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES